21Feb 2017

Prevalence of hepatitis B and C among some high risk groups in Egyptian children attending Benha University hospital.

  • Pediatrics Department, Faculty of Medicine, Benha University, Benha, Egypt.
  • Medical Biochemistry Department and Molecular Biology and Biotechnology Unit, Faculty of Medicine, Benha University, Benha, Egypt.
  • Public Health Department, Faculty of Medicine, Benha University, Benha, Egypt.
Crossref Cited-by Linking logo
  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

Background: Hepatitis C virus (HCV) is a global health problem especially in Egypt. Hepatitis B virus (HBV) is a major cause of chronic liver diseases especially cirrhosis and hepatocellular carcinoma. HBV incidence is markedly reduced after mass vaccination programs application. Objectives: to detect HCV and HBV seroprevalence among some high risk children with molecular confirmation of viremia by real-time PCR for seropositive cases. Materials and methods: A comparative cross sectional study was conducted on 5 groups of Egyptian children attending Benha University Hospital (diabetes mellitus, thalassemia, hemodialysis, previously exposed to surgery and healthy children). All children were subjected to full history taking, physical examination and laboratory investigations including HCV antibodies by 4th generation ELISA, HBsAg, HBsAb using ELISA, liver function tests and CBC, HCV and HBV viremia detection by real-time PCR for ELISA positive subjects. Results: HCV seropositivity was detected in 5%, 15%, 30%, 50% and 10% for healthy, diabetic, thalassemia, hemodialysis and previously exposed to surgery, respectively. As regard HBV, only a hemodialysis case was positive for both HBsAg and HBV-DNA. Low social class, blood transfusion, frequent intravenous injection, previous surgery and previous hospitalization are major risk factors for HCV transmission. Conclusion: The study revealed high HCV seropositivity prevalence among the studied high risk groups. PCR should be done for all HCV seropositive cases to confirm the presence of viremia.


  1. ElShabrawi M, Hassanin F. Treatment of hepatitis B and C in children. Minerva Pediatr. 2014? 66:473-89.
  2. McHutchison JG. Understanding hepatitis C. Am J Manag Care 2004; 10:S21-9.
  3. El-Guindi MA. Hepatitis C Viral Infection in Children: Updated Review. Pediatr Gastroenterol Hepatol Nutr.2016; 19:83-95.
  4. Gower EEstes CBlach SRazavi-Shearer KRazavi H (2014). Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol.2014; 61(1 Suppl): S45-57.
  5. Wang CS, Chang TT, Yao WJ, Chou P. Comparison of hepatitis B virus and hepatitis C virus prevalence and risk factors in a community-based study. Am J Trop Med Hyg. 2002; 66: 389-393.
  6. El Zanaty F, Way A. Egypt demographic and health survey 2008, Egypt Ministry of Health. Egypt: Cairo: El-Zanaty and Associates, and Macro International; 2009.
  7. Alter MJ. Prevention of spread of hepatitis C. Hepatology 2002; 36 (5 supp1): S93-98.
  8. Raja NS and Janjua KA. Epidemiology of hepatitis C virus infection in Pakistan J Microbiol I mmunol Infect 2008; 41:4-8.
  9. Masuda H, Atsumi T, Fujisaku A, Shimizu CYoshioka NKoike T. Acute onset of type 1 diabetes accompanied by acute hepatitis C: The potential role of proinflammatory cytokine in the pathogenesis of autoimmune diabetes. Diabetes Res Clin Pract. 2007; 75: 357-361.
  10. Mansour AKAly RMAbdelrazek SYElghannam DMAbdelaziz SMShahine DA et al. Prevalence of HBV and HCV infection among multi-transfused Egyptian thalassemic patients. Hematol Oncol Stem Cell Ther.2012; 5: 54-9.
  11. Khodir SA, Alghateb M,Okasha KM, Shalaby Sel-S. Prevalence of HCV infection amonge haemodialysis patients in Al Gharbiyah Governorate, Egypt. Arab J of Nephrol Transplant. 2012; 5:145-7.
  12. Ali I, Siddique L, Rehman LU, Khan NU, Iqbal A, Munir I, et al. Prevalence of HCV among the high risk groups in Khyber Pakhtunkhwa. Virol J. 2011; 8: 296.
  13. Fahmy SI and El-Sherbiny AF. Determining simple parameters for social classification for social health research. Bulletin of the High Institute of Public Health 1983; 13: 95-108.
  14. Buttarello M and Plebani M. Automated blood cell counts: state of the art. American journal of clinical pathology 2008; 130: 104–16.
  15. Reitman S and Frankel S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. American J Clin Pathol 1957; 28: 56 -63.
  16. Malloy HT and Evelyn K. The determination of bilirubin with the photoelectric colorimeter. Biol Chem J 1937; 119: 481-490.
  17. Grakoui A, Wychowski C, Lin C, Feinstone SM and Rice CM. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 1993; 67: 1385- 95.
  18. Blumberg BS, Sutnick AI, London WT and Millman J. The discovery of Australian antigen and its relation to viral hepatitis. Perspect Virology 1971; 7: 223-40.
  19. Zanetti A, Parlato A, Roman L, Desole MG, Ferrera G, Giurdanella F et al. Challenge with a hepatitis B vaccine in two cohorts of 4–7-year-old children primed with hexavalent vaccines: An open-label, randomised trial in Italy. Vaccine; 2012; 30: 5770– 5775.
  20. Shouval D (2003): Hepatitis B vaccines, Journal of Hepatology; 39:S70-76.
  21. von Schaewen M, Dorner M, Hueging K, Foquet L, Gerges S, Hrebikova G, et al. Expanding the Host Range of Hepatitis C Virus through Viral Adaptation. 2016;7: pii: e01915-16.
  22. Barakat SH and El-Bashir N. Hepatitis C virus infection among healthy Egyptian children: prevalence and risk factors. J Viral Hepat.2011; 18: 779-84.
  23. Mohamoud YAMumtaz GRRiome SMiller DAbu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis.2013; 13:288.
  24. Mostafa ATaylor SMel-Daly Mel-Hoseiny MBakr IArafa NThiers VRimlinger FAbdel-Hamid MFontanet AMohamed MK. Is the hepatitis C virus epidemic over in Egypt? Incidence and risk factors of new hepatitis C virus infections. Liver Int.2010; 30:560-6.
  25. Aceijas C and Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007; 18: 352-8.
  26. Paez Jimenez ASharaf Eldin NRimlinger FEl-Daly MEl-Hariri HEl-Hoseiny M. HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. 2010; 59:1554-60.
  27. Kalil KAFarghally HSHassanein KMAbd-Elsayed AAHassanein FE. Hepatitis C virus infection among paediatric patients attending University of Assiut Hospital, Egypt. East Mediterr Health J.2010; 16:356-61.
  28. El-Karaksy HM, Anwar G, Esmat G, Mansour S, Sabry M, Helmy H, et al. Prevalence of hepatic abnormalities in a cohort of Egyptian children with type 1 diabetes mellitus. Pediatr Diabetes.2010; 11: 462–70.
  29. Desenclos JC, Bourdiol-Raz'es M, Rolin B, Garandeau P, Ducos J, Brechot C, et al. Hepatitis C in a ward for cystic fibrosis and diabetic patients: Possible transmission by spring-loaded finger-stick devices for self-monitoring of capillary blood glucose. Infect Control Hosp Epidemiol. 2001; 22:701–7.
  30. Din GMalik SAli IAhmed SDasti JI. Prevalence of hepatitis C virus infection among thalassemia patients: a perspective from a multi-ethnic population of Pakistan. Asian Pac J Trop Med.2014; 7S1:S127-33.
  31. Alavian SM (2007): Control of hepatitis C in Iran: vision and missions. Hepat Mon.7:57-8.
  32. Alavian SMGholami BMasarrat S. Hepatitis C risk factors in Iranian volunteer blood donors: a case-control study. J Gastroenterol Hepatol.2002; 17:1092-7.
  33. Xia XLuo JBai JYu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review andmeta-analysis. Public Health.2008; 122:990-1003.
  34. Nemati EAlavian SMTaheri SMoradi MPourfarziani VEinollahi B. Hepatitis C virus infection among patients on hemodialysis: a report from a single center in Iran. Saudi J Kidney Dis Transpl.2009; 20:147-53.
  35. Abed NT, Elfeky OA, Fouda ME, Eldesouky RSh, Ahmed ES. Prevalence and risk factors of asymptomatic hepatitis C virus infection among a sample of school aged Egyptian children. International Journal of Medical and Health Sciences. 2016; 5:87-93.
  36. Egyptian Renal Registry: 2008 report, ESNT congress, Hurghada Egypt, February, 2009.
  37. Bastiani MF; Baiocco GG; Wagner SC. Prevalence of hepatitis C in patients with renal disease undergoing hemodialysis treatment. 2014; J Bras Patol Med Lab 50: 327-331.
  38. Zhao QWen YJiang YZhang CLi YZhang G et al. Next Generation Sequencing-Based Investigation of Potential Patient-to-Patient Hepatitis C VirusTransmission during Hemodialytic Treatment. PLoS One.2016; 11:e0147566.
  39. Halle MPChoukem SPKaze FFAshuntantang GTchamago VMboue-Djieka Y et al. Hepatitis B, hepatitis C, and human Immune deficiency virus seroconversion positivity rates and their potential risk factors among patients on maintenance hemodialysis in Cameroon. Iran J Kidney Dis.2016; 10:304-309.
  40. Masood Z, Jawaid M, Khan RA, ur Rehman S. Screening for Hepatitis B and C: A routine preoperative investigation. Pak J Med Sci 2005; 21: 455-9.
  41. Chaudhry IA, Khan SS, Majrooh MA, Alvi AA. Seroprevalence of Hepatitis B and C among the patients reporting at OPD at Fauji Foundation on Hospital Rawalpindi .Pak J Med Sci 2007; 23:514-17
  42. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology, 2002;122:1554-68
  43. Villa E, Grottola A, Buttafoco P, Trande P, Merighi A, Fratti N et al. Evidence for hepatitis B virus infection in patients with chronic hepatitis C with and without serological markers of hepatitis B. Dig Dis Sci.1995; 40: 8-13.
  44. Maillard PKrawczynski KNitkiewicz JBronnert CSidorkiewicz MGounon P et al. Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. J Virol.2001; 75: 8240-50.
  45. Bhattacharya SBadrinath SHamide ASujatha S. Co-infection with hepatitis C virus and human immunodeficiency virus among patients with sexually transmitted diseases in Pondicherry, South India. Indian J Pathol Microbiol.2003; 46:495-7.
  46. Wahib AASeif El Nasr MSMangoud AMEl Shazly AMMorsy AT. The liver function profile in PCR-RNA Egyptian HCV-patients and normal controls. J Egypt Soc Parasitol.2005; 35:451-66.
  47. Eldesoky A, Mosaad Y, Zakria Y, Hamdy S. Protective Immunity After Hepatitis B Vaccination Arab Journal of Gastroenterology 2009; 10: 68-71.
  48. Khashaba A, El-Defrawy M, Abdel Motaleb G, El-Shafaey M and Rashad G. Study of the immune response of hepatitis B vaccination in Egyptian pre-school children. Benha Medical Journal; 2005; 22:515-525.
  49. Jafarzadeh AMontazerifar SJ. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth. J Ayub Med Coll Abbottabad.2006; 18: 4-9.
  50. Fiore AE,  Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, CDC: 2006; 55(RR07):1-23.

[Mohamed Elsherbiny, Neveen Tawfik Abed, Shuzan Ali Mohammed, Mona El-Awady and Nagwa Khairy Kattab. (2017); Prevalence of hepatitis B and C among some high risk groups in Egyptian children attending Benha University hospital. Int. J. of Adv. Res. 5 (Feb). 928-936] (ISSN 2320-5407). www.journalijar.com


Mona Ahmed Elawady


DOI:


Article DOI: 10.21474/IJAR01/3237      
DOI URL: http://dx.doi.org/10.21474/IJAR01/3237